Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Publikation

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Wissenschaftlicher Artikel/Review - 18.06.2018

Schäfer Niklas, Proescholdt Martin, Steinbach Joachim P, Weyerbrock Astrid, Hau Peter, Grauer Oliver, Goldbrunner Roland, Friedrich Franziska, Rohde Veit, Ringel Florian, Schlegel Uwe, Sabel Michael, Ronellenfitsch Michael W, Uhl Martin, Grau Stefan, Hänel Mathias, Schnell Oliver, Krex Dietmar, Vajkoczy Peter, Tabatabai Ghazaleh, Mack Frederic, Schaub Christina, Tzaridis Theophilos, Nießen Michael, Kebir Sied, Leutgeb Barbara, Urbach Horst, Belka Claus, Stummer Walter, Glas Martin, Herrlinger Ulrich

Zitation

Schäfer N, Proescholdt M, Steinbach J, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol 2018; 20:975-985.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Neuro Oncol 2018; 20

Veröffentlichungsdatum

18.06.2018

eISSN (Online)

1523-5866

Seiten

975-985

Kurzbeschreibung/Zielsetzung

The GLARIUS trial, which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide in the first-line therapy of O6-methylguanine-DNA methyltransferase (MGMT)-nonmethylated glioblastoma, showed that progression-free survival was significantly prolonged by BEV/IRI, while overall survival was similar in both arms. The present report focuses on quality of life (QoL) and Karnofsky performance score (KPS) during the whole course of the disease.